












## Research Article

# Neurocognitive outcome and associated factors in long-term, adult survivors of childhood acute lymphoblastic leukemia, treated without cranial radiation therapy

Kaja Solland Egset<sup>1</sup> , Jan Stubberud<sup>2,3</sup> , Ellen Ruud<sup>4,5</sup> , Magnus Aassved Hjort<sup>6,7</sup> ,  
Mary-Elizabeth Bradley Eilertsen<sup>8</sup> , Anne Mari Sund<sup>9</sup> , Odin Hjemdal<sup>1</sup> , Siri Weider<sup>1</sup>  and Trude Reinfjell<sup>1</sup> 

<sup>1</sup>Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway, <sup>2</sup>Department of Psychology, University of Oslo, Oslo, Norway, <sup>3</sup>Department of Research, Lovisenberg Diaconal Hospital, Oslo, Norway, <sup>4</sup>Division for Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway, <sup>5</sup>Faculty of Medicine, University of Oslo, Oslo, Norway, <sup>6</sup>Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, <sup>7</sup>Children's Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, <sup>8</sup>Department of Public Health and Nursing, Center for Health Promotion Research, Norwegian University of Science and Technology, Trondheim, Norway and <sup>9</sup>Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian University of Science and Technology, Trondheim, Norway

## Abstract

**Objective:** There is limited research on neurocognitive outcome and associated risk factors in long-term, adult survivors of childhood acute lymphoblastic leukemia (ALL), without treatment of cranial radiation therapy. Moreover, the impact of fatigue severity and pain interference on neurocognition has received little attention. In this cross-sectional study, we examined neurocognitive outcome and associated factors in this population. **Method:** Intellectual abilities, verbal learning/memory, processing speed, attention, and executive functions were compared to normative means/medians with one sample *t* tests or Wilcoxon signed-rank tests. Associations with risk factors, fatigue severity, and pain interference were analyzed with linear regressions. **Results:** Long-term, adult survivors of childhood ALL ( $N = 53$ , 51% females, mean age = 24.4 years,  $SD = 4.4$ , mean = 14.7 years post-diagnosis,  $SD = 3.4$ ) demonstrated above average intellectual abilities, but performed below average in attention, inhibition, processing speed, and shifting ( $p < 0.001$ ). Executive functioning complaints were significantly higher than normative means, and positively associated with fatigue ( $p < 0.001$ ). There was no interaction between sex and fatigue and no neurocognitive impairments were associated with pain interference, risk group, age at diagnosis, or sex. **Conclusions:** Long-term, adult survivors of ALL treated without cranial radiation therapy, demonstrate domain-specific performance-based neurocognitive impairments. However, continued research on the neurocognitive outcome in this population as they age will be important in the coming years. Executive functioning complaints were frequently in the clinical range, and often accompanied by fatigue. This suggests a need for cognitive rehabilitation programs.

**Keywords:** Cancer survivors; cognitive dysfunction; executive function; follow-up studies; fatigue; cancer pain

(Received 16 August 2023; final revision 12 January 2024; accepted 4 February 2024; First Published online 11 March 2024)

## Introduction

Acute lymphoblastic leukemia (ALL) is the most common diagnosis of childhood cancer. As a result of tremendous improvements in modern treatment, the five-year event-free survival is now approaching 90% in developed countries (Jeha et al., 2019; Toft et al., 2018). However, research suggests that a subgroup of survivors show neurocognitive sequelae many years into survivorship (Krull et al., 2013).

In childhood ALL survivors, neurocognitive sequelae have traditionally been attributed to cranial radiation therapy (Hardy et al., 2018; Krull et al., 2018). Cranial radiation therapy has been shown to impact the severity of neurocognitive impairments, with

higher doses relating to higher severity rates (Zhou et al., 2020). To help preserve neurocognitive functions, the treatment has gradually been replaced by intrathecal chemotherapy. Cranial radiation therapy was first omitted from the treatment of standard risk ALL in the 1980s (Hudson et al., 2012; Schmiegelow et al., 2010; Toft et al., 2018). From the year of the 2000 and onward, increasingly more patients with high-risk disease have also been cured without cranial radiation therapy (Pui & Evans, 2013). Although chemotherapeutic agents appear to have less severe effects on neurocognition (Cheung & Krull, 2015), adverse brain changes (e.g., white matter reduction) (Zhou et al., 2020), and neurocognitive sequelae (van der Plas, Modi, et al., 2021) have been demonstrated in survivors of childhood ALL treated without

**Corresponding author:** Kaja Solland Egset; Email: [kaja.solland.egset@ntnu.no](mailto:kaja.solland.egset@ntnu.no)

**Cite this article:** Egset K.S., Stubberud J., Ruud E., Hjort M.A., Eilertsen M.-E.B., Sund A.M., Hjemdal O., Weider S., & Reinfjell T. (2024) Neurocognitive outcome and associated factors in long-term, adult survivors of childhood acute lymphoblastic leukemia, treated without cranial radiation therapy. *Journal of the International Neuropsychological Society*, 30: 523–532, <https://doi.org/10.1017/S1355617724000080>

© The Author(s), 2024. Published by Cambridge University Press on behalf of International Neuropsychological Society. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

cranial radiation therapy as well. Studies of long-term (min. five years post-diagnosis, Cheung & Krull, 2015) survivors in adulthood have documented mostly normal intellectual functions with specific impairments related to processing speed, attention, memory, and executive functions (Chiou *et al.*, 2019; Edelmann *et al.*, 2013; Elens *et al.*, 2017; Kanellopoulos *et al.*, 2016; Krull *et al.*, 2013). Executive functions are higher-level cognitive control processes, which contribute to the regulation of thoughts and goal-directed behavior (Friedman & Miyake, 2017; Miyake & Friedman, 2012), essential for adult daily-life and wellbeing (Friedman & Miyake, 2017). However, a long period of follow-up time is needed to evaluate neurocognitive outcome in adulthood. As such, there are still few studies that have examined neurocognitive outcome associated with contemporary chemotherapy protocols in this population (Schmiegelow *et al.*, 2010; Toft *et al.*, 2018).

Most research has focused on treatment and disease factors in relation to neurocognitive outcome. It has previously been stated that treatment burden (Hardy *et al.*, 2018; Krull *et al.*, 2018), female sex (Krull *et al.*, 2013; van der Plas, Qiu, *et al.*, 2021), and younger age at diagnosis (Jacola *et al.*, 2016; Sherief *et al.*, 2018) increase the likelihood of neurocognitive sequelae. However, there is also a need to explore additional moderating factors, to facilitate the identification, rehabilitation, and prognosis of neurocognitive impairments (Zhou *et al.*, 2020).

A prevalent (Hamre *et al.*, 2013; van Deuren *et al.*, 2022), distressing (Hamre *et al.*, 2013; Kanellopoulos *et al.*, 2013), and relatively persistent (Irestorm *et al.*, 2023; Zeller *et al.*, 2014) symptom in survivors of childhood ALL is fatigue. Fatigue may be described as “a sense of tiredness and lack of energy, distinct from sadness and weakness” (Krupp *et al.*, 1988). Approximately ¼ of childhood ALL survivors report severe fatigue in adulthood (van Deuren *et al.*, 2022). While several studies have demonstrated an association between fatigue and mental distress, research regarding the association with neurocognition is surprisingly limited (van Deuren *et al.*, 2020). Earlier research has revealed an association between fatigue and neurocognitive impairments (Clanton *et al.*, 2011), which may be explained by a lower mental capacity in fatigued individuals (Meeske *et al.*, 2005). However, this research is limited by self-report methodology only (Clanton *et al.*, 2011) and poorly specified neurocognitive domains (Meeske *et al.*, 2005; Rueegg *et al.*, 2013). In addition, one study on long-term adolescent survivors showed that females are especially vulnerable to the effects of fatigue on executive functions, processing speed, and attention (Cheung *et al.*, 2017). Still, little is known about this sex difference in adulthood.

Long-term survivors of ALL also report increased levels of tension headaches, migraines (Khan *et al.*, 2014), and back pain (Bowers *et al.*, 2012). Some survivors experience neuropathy (Kandula *et al.*, 2016), which can cause burning pain, numbness or hypersensitivity to touch. With the development of more effective cancer treatment for childhood ALL, there has been an increase in reports of cancer-related pain (Ness *et al.*, 2017). This could possibly be due to more children with higher risk disease, being cured by more intensive treatments (e.g., >10 doses of intrathecal chemotherapy (Khan *et al.*, 2014)), in the more recent cohorts. As such, pain could be a particularly relevant factor in understanding neurocognitive sequelae following contemporary chemotherapy regimens. Due to the biological salience of pain (Moriarty *et al.*, 2011), pain may occupy a significant amount of cognitive resources (e.g., attention) (Stone *et al.*, 2018) and have a negative impact on neurocognitive performance (Moriarty *et al.*, 2011). Consistent with this idea, emerging research shows that pain interference in long-term, adult survivors of childhood cancer has adverse effects

on the performance of attention, executive functions, processing speed, and memory (Tonning Olsson *et al.*, 2021). However, the impact of pain interference on neurocognition in long-term survivors of childhood ALL specifically, remains to be examined (Stone *et al.*, 2018).

The first aim of the current study was to map neurocognitive outcome in long-term survivors of childhood ALL, treated with chemotherapy, but without cranial radiation therapy. Both performance-based and self-report measures were used for this purpose. The second aim of this study was to examine factors associated with neurocognitive outcome in this population. We examined the impact of known risk factors (i.e., age at diagnosis, sex, and disease/treatment burden) on neurocognitive functioning. It was hypothesized that younger age at diagnosis, female sex, and more intensive treatment increased the risk of poor neurocognitive outcome. Furthermore, we explored the influence of pain interference and fatigue severity on neurocognitive functioning and whether females were more vulnerable to the effects of fatigue on neurocognition in adulthood. It was expected that fatigue and pain would negatively affect neurocognition.

## Methods

### *Participants and procedures*

The Cancer Registry of Norway identified all individuals diagnosed with ALL between 1980 and 2015 at age below 18 and minimum five years post-diagnosis, in the South-Eastern and Middle regions of Norway. Adults (>18 and <40 years) who were alive in 2020 and 2021, without relapse of ALL within the last five years, and treated at Oslo University Hospital or St. Olavs Hospital in Norway, were eligible to participate in the study. Individuals with a history of premorbid CNS disease or injury (e.g., cerebral palsy) were excluded. The study was part of a larger clinical trial (clinicaltrials.gov: NCT04541056) where participants with executive functioning complaints were further invited to participate in cognitive rehabilitation. It was clearly stated that neurocognitive sequelae were not a prerequisite for participation in the present study. A total of 143 individuals received an invitation letter, with 57 individuals eventually participating (40% participation rate). The research was completed in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants and the study was approved by the Regional Committee for Medical Research Ethics in Central Norway (2018/1810). Three participants were excluded from analyses due to substance abuse and a sensory impairment. One was not included due to having received cranial radiation therapy. Thus, a total of 53 survivors (Mean age = 24.40, *SD* = 4.41, 51% females) are included in the current study (Table 1).

Demographic and treatment characteristics were collected from a semi-structured interview, The Cancer Registry and the participants' hospital records. From the latter, we collected information about diagnosis, date of diagnosis and treatment start, treatment protocols, stem cell transplantation, radiation therapy, and relapse. All participants had received ALL treatment according to a strict protocol, most frequently NOPHO ALL 2000 (Schmiegelow *et al.*, 2010) (*N* = 35) and NOPHO ALL 2008 (Toft *et al.*, 2018) (*N* = 13). Treatment duration for these protocols is 2–2.5 years from diagnosis (Schmiegelow *et al.*, 2010). The remaining (*N* = 5) had received other treatment protocols (e.g., Hammersmith/modified Hammersmith) (Bersvendsen *et al.*, 2014). The protocols stratified between a high-risk and a non-high-risk treatment approach based on biological factors associated with prognosis. The high-risk approaches had more intensive, more types, and higher cumulative doses of chemotherapy.

**Table 1.** Demographic characteristics of the sample ( $N = 53$ )

	$N$ (%)	$M$ ( $SD$ )	Min.	Max.
Female	27 (51)			
Age at participation	53	24.40 (4.41)	18	34
Education level	52	14.29 (2.31)	9	20
Years from diagnosis	53	14.41 (3.61)	5.61	19.61
Age at diagnosis	53	10.08 (5.21)	1	17
Diagnosed before age five	12 (22)			
Center	53			
Oslo University Hospital	36 (68)			
St. Olavs Hospital	17 (32)			
Year of diagnosis*	53	2005	2002	2015
Allogeneic stem cell transplantation	6 (11)			
Relapse	3 (6)			
ALL HR treatment	17 (32.1)			

Note.  $M$  = mean,  $SD$  = standard deviation. Education level = years of education. \*Median reported for year of cancer diagnosis. ALL = acute lymphoblastic leukemia, HR = high-risk.

Details and exact doses of chemotherapy are not collected in this study.

Participants took part in neurocognitive testing and completed self-report questionnaires. Neurocognitive testing took place in a dedicated room and lasted approximately four hours including short breaks. The order of testing was fixed. Survivors were offered the opportunity to participate over two subsequent days, and all survivors had a one-hour lunch break. Participants who were unable to attend physically (e.g., due to the Covid-19 pandemic), were asked to respond to self-report questionnaires only ( $N = 2$ ). Various infection control measures (e.g., plexiglass, disinfection of material) were employed during testing.

## Measures

### Performance-based neurocognitive tests

The subtests Block design, Matrix reasoning, Similarities, and Vocabulary (scaled scores,  $M = 10$ ,  $SD = 3$ ) from the Wechsler Adult Intelligence Scale-IV (WAIS-IV) (Wechsler, 2008) were used to calculate the general ability index (GAI, IQ scores,  $M = 100$ ,  $SD = 15$ ) as an estimation of intellectual functioning. In addition, the Digit span and Letter-number sequencing were used as measures of working memory capacity (Scaled scores,  $M = 10$ ,  $SD = 3$ ).

*California Verbal Learning Test 2nd Edition* (CVLT-II) was used to characterize auditory attention span, verbal learning and memory. List A, trial 1 ( $M = 0$ ,  $SD = 3$ ) was used to assess auditory attention span, the overall correct recall from list A 1-5 ( $M = 50$ ,  $SD = 10$ ) was used to assess verbal learning. Short-delay free recall and long-delay free recall ( $M = 0$ ,  $SD = 3$ ) were used to measure verbal memory.

*Conner's Continuous Performance Test 3rd Edition* (CPT-3) (Conners, 2014) was used to assess inhibitory control and focused attention ( $M = 50$ ,  $SD = 10$ ). Specifically, Commissions and detectability were employed as measures of inhibitory control and focused attention respectively. Scores were converted to  $T$ -scores ( $M = 50$ ,  $SD = 10$ ) and reversed so that higher scores reflect fewer commission errors and better performance.

*The Trail Making Test* (TMT) from the DKEFS (Delis et al., 2001) was used to measure cognitive set-shifting (condition 4). Here, the participant is asked to shift between number and letter sequencing. To assess processing speed, conditions 2 (number sequencing) and 3 (letter sequencing) were employed. Scores reflect completion time, and raw scores were converted to scaled scores ( $M = 10$ ,  $SD = 3$ ), where higher scores reflect better performance.

*The Color-Word Interference test* (CWIT) from the Delis-Kaplan Executive Function System (DKEFS) was used to assess inhibition and cognitive set-shifting (Delis et al., 2001). Condition 3 was used for inhibition and condition 4 was employed as a measure of set-shifting. To assess processing speed, conditions 1 (color naming) and 2 (word reading) were used. Primary scores were computed for completion time, and raw scores were converted to scaled scores ( $M = 10$ ,  $SD = 3$ ), where higher scores reflect better performance.

A computer-based version of The Wisconsin Card Sorting Test (WCST-4) (Heaton & Staff, 1993) used to assess set-shifting and problem-solving capacity (Lezak et al., 2012).  $T$ -scores ( $M = 50$ ,  $SD = 10$ ) were generated, with higher scores reflecting better performance.

### Self-report questionnaires

*Behavior Rating Inventory of Executive Functioning – Adult Version* (BRIEF-A) (Gioia, 2000; Roth et al., 2005) was used to assess the perception of daily-life executive functions. Participants report the frequency of daily-life executive functioning problems (e.g., I have trouble finding things, in my room, in my closet, on my desk) during the past six months on a scale from 1 (Never) to 3 (Often). The questionnaire provides the summary score Global Executive Composite (GEC) and the two index scores: the Behavioral Regulation Index (BRI) and the Metacognitive Index (MI). The BRI includes the subscales of Inhibit, Shift, Emotional control and Self-monitor and reflects the behavioral and emotional aspects of executive functions. The MI includes the subscales Initiate, Working Memory, Plan/Organize, Task Monitor and Organization of Materials and reflects the cognitive aspects of executive functions. Raw scores were converted to  $T$ -scores ( $M = 50$ ,  $SD = 10$ ), where higher scores indicate worse executive functions. The recommended clinical cutoff for this measure is  $T \geq 65$  (Roth et al., 2005). Data from healthy Norwegian adults indicate that the normative mean in Norway is at least  $\frac{1}{2}$  SD below that of the U.S. normative mean (i.e.,  $M = 45$ ) (Løvstad et al., 2016), suggesting a clinical cutoff of  $T \geq 60$  might be more appropriate.

*The Fatigue Severity Scale* (FSS) was used to characterize fatigue (Krupp et al., 1989). Participants responded to statements about how fatigue interferes with certain activities, on a scale from 1 (strongly disagree) to 7 (strongly agree). FSS has been used to measure fatigue in multiple clinical populations (Lerdal, 2021). High correlations between FSS and other measures of fatigue (e.g.,  $r = -0.76$  with the vitality scale from Short-Form-36) and excellent

test–retest reliability have been reported (Gencay-Can & Can, 2012; Kleinman et al., 2000). Additionally, good psychometric properties have been demonstrated for the Norwegian version of FSS, with satisfactory reliability (i.e., internal consistency (Lerdal et al., 2005)). Based on previous reports on the prevalence of fatigue in the Norwegian population, a FSS score  $\geq 5$  was interpreted as indicative of severe fatigue (Schanke et al., 2002).

*Patient reported outcome measure system (PROMIS) short form, version 1.1-Pain Interference* was employed to evaluate pain interference in the participant's life. The degree to which pain interferes with daily-life (i.e., family life, work, social activity) was reported on eight items, scaled from 1 (not at all) to five (very much). *T*-scores ( $M = 50$ ,  $SD = 10$ ) were calculated using the online scoring at [www.assessmentcenter.net/ac\\_scoringervice](http://www.assessmentcenter.net/ac_scoringervice). The Norwegian version has shown adequate reliability and validity, indicating that the measure is suitable for use in the Norwegian population (Rimehaug et al., 2022).

### Statistical analysis

Statistics were analyzed in SPSS 28 and STATA 17. Differences in age, age at diagnosis, follow-up time and sex between participants and non-participants were examined. A chi-square test of homogeneity, independent sample *t* test or Mann–Whitney *U* test was used for this purpose. One sample *t* tests or Wilcoxon signed-rank tests were performed to compare the sample neurocognitive performance and executive functioning complaints to the normative means or medians. Preliminary analyses were conducted to determine whether assumptions (i.e., normality and no outliers) were violated. Boxplots, histograms, QQ-plots, values of skewness and kurtosis, Shapiro–Wilk were inspected. If assumptions were violated, a non-parametric statistical test was employed (i.e., Wilcoxon signed-rank test). A significance value of  $p < 0.01$  was used to partially control for multiple comparisons.

Furthermore, multiple linear regression analyses were performed to evaluate factors associated with neurocognitive outcome (i.e., performance and self-reported). Analyses to assess assumptions related to linearity, homoscedasticity, outliers, multicollinearity, and normality were conducted. Risk factors (age at diagnosis, sex, risk group), fatigue severity, and pain interference were entered as independent variables. Risk group was used as a measure of disease severity and treatment intensity. Participants were categorized into non-high-risk or high-risk based on risk stratification associated with their treatment protocols (e.g., NOPHO ALL 2000 and 2008) (Schmiegelow et al., 2010; Toft et al., 2018). In cases where participants had been treated with Hammersmith protocols (Bersvendsen et al., 2014), IntReALL protocols (von Stackelberg et al., 2022; von Stackelberg et al., 2017), protocols for Philadelphia positive ALL (Biondi et al., 2012), and/or had a relapse or stem cell transplantation, they were categorized into the high-risk group. Age at diagnosis was calculated as the time from date of birth (month and year) to date of diagnosis (month and year). If date of the diagnosis was missing, the date of chemotherapy treatment start was used. For the regression analyses, age at diagnosis was dichotomized into under/over 10 years. Exploratory *t* tests comparing neurocognitive outcome between participants under/over five years at diagnosis were performed as well. To explore whether females were more vulnerable to the effects of fatigue on neurocognitive outcome, the interaction between sex and fatigue severity was analyzed. A significance value of  $p < 0.01$  was used to partially control for multiple analyses.

## Results

### Demographic and treatment characteristics

A comparison of participants and eligible non-participants can be found in Supplementary Table 2. Median age at investigation was significantly higher in participating survivors than non-participants. Participants also had a higher age at diagnosis compared to non-participants treated at Oslo University Hospital.

Demographic and treatment characteristics of the sample are reported in Table 1. According to the semi-structured interview, none ( $N = 52$ , missing = 1) had received cognitive rehabilitation at the time of study participation. However, one participant used stimulant medication (i.e., Ritalin) and two had received rehabilitation directed at chronic fatigue.

### Neurocognitive outcome

Survivors demonstrated significantly better general intellectual abilities, but significantly poorer auditory attention span (CVLT-II, list A trial 1), inhibitory control (CPT-3 commissions), and oral processing speed (CWIT color naming) compared to the normative mean (Table 2). Although shifting (cond. 4, TMT, cond. 4, CWIT, pers. response, WCST-4) was not significantly different from the normative mean, performance was significantly poorer than the normative mean when we controlled for processing speed (TMT, shifting vs. combined number letter sequencing). We examined these domains in greater detail to establish how many participants might be classified as having a neurocognitive impairment (i.e., score 1.5 *SD* below the normative mean). The number of participants showing an impairment was 12 (24%) for auditory attention span (CVLT-II, list A trial 1), 13 (26%) for inhibitory control (CPT-3, commissions), 14 (28%) for shifting (TMT, switching vs. combined number letter sequencing), and 18 (35%) for oral processing speed (CWIT color naming). On a group level, there were no impairments in working memory (WAIS-IV, digit span, letter-number sequencing), verbal learning and memory (CVLT-II, list A trial 1-5, short and long delay), problem-solving/set-shifting (WCST-4, pers. response, pers. errors), and visual processing speed (TMT number sequencing).

Self-reported executive functioning complaints were significantly higher than the US normative mean for the summary scores MI and GEC. The subscales shift, initiate, working memory, plan/organize, and task monitor were all significantly higher than the normative mean. When we examined self-reported executive functioning complaints in greater detail, 16 (30%) and 11 (21%) scored above the U.S. clinical cutoff  $T \geq 65$  for the MI and GEC scales respectively. We examined the number of clinical cases based on the Norwegian cutoff of  $T \geq 60$  as well. This resulted in an even higher level of clinical cases with 25 (47%) in the MI domain and 19 (36%) in the GEC.

### Risk factors and predictors of neurocognitive outcome

None of the domains identified as neurocognitive impairments were significantly associated with any of the risk factors, age at diagnosis (under/over 10 years), risk group (high-risk vs. non-high risk), and sex (Table 3). Exploratory *t* tests did not show significant differences between participants diagnosed before and after five years of age.

The descriptive statistics for fatigue severity and pain interference are reported in Table 4. Furthermore, multiple linear regression analyses showed that fatigue severity was significantly associated with both self-reported metacognitive and general executive functioning complaints (Table 5). However, no significant associations were found for auditory attention span,

**Table 2.** Performance-based and self-reported neurocognitive outcome

	<i>N</i>	<i>M</i> ( <i>SD</i> )	<i>P</i>	Cohen's <i>d</i>
<b>WAIS-IV</b>				
General ability index*	51	109.37 (18.10)	<0.001	.52
Digit span <sup>†</sup>	51	9.6 (2.62)	0.27	
Number letter sequencing <sup>†</sup>	51	9.9 (1.90)	0.24	
<b>CVLT-II</b>				
List A trial 1 correct recall*	51	-.48	0.001	-.49
Overall correct recall list A 1-5*	51	51.59 (10.34)	0.28	.15
Short delay free recall <sup>†</sup>	51	.40 (1.15)	0.005	
Long delay free recall <sup>†</sup>	51	.27 (1.15)	0.05	
<b>CPT-3</b>				
Detectability*	51	46.88 (9.56)	0.02	-.33
Commissions*	51	44.27 (10.90)	<0.001	-.53
<b>TMT</b>				
Condition 1 <sup>†</sup>	51	10.3 (2.52)	0.14	
Condition 2 <sup>†</sup>	51	10.9 (2.52)	<0.001	
Condition 3 <sup>†</sup>	51	10.2 (3.20)	0.12	
Condition 4 <sup>†</sup>	51	9.9 (2.74)	0.95	
Switching vs. combined number/letter sequencing*	51	8.84 (2.28)	<0.001	-.51
<b>CWIT</b>				
Condition 1*	51	8.78 (2.27)	<0.001	-.57
Condition 2 <sup>†</sup>	51	9.4 (2.41)	0.07	
Condition 3 <sup>†</sup>	51	9.9 (3.02)	0.60	
Condition 4 <sup>†</sup>	51	9.2 (3.28)	0.19	
<b>WCST-4</b>				
Pers. error <sup>†</sup>	50	55.21 (11.24)	0.034	
Pers. response <sup>†</sup>	50	56.58 (12.41)	0.012	
<b>BRIEF-A</b>				
Inhibit <sup>†</sup>	53	51.72 (9.08)	0.42	
Shift*	53	56.70 (11.44)	<0.001	.59
Emotional control <sup>†</sup>	53	51.94 (11.77)	0.33	
Self-monitor <sup>†</sup>	53	49.00 (10.76)	0.47	
BRI*	53	52.70 (10.31)	0.06	.26
Initiate*	53	61.02 (12.20)	<0.001	.90
Working memory*	53	62.70 (12.84)	<0.001	.99
Plan/Organize*	53	57.74 (11.54)	<0.001	.67
Task monitor*	53	57.19 (10.29)	<0.001	.70
Organization of materials*	53	49.26 (9.22)	0.56	-.08
MI*	53	58.60 (10.70)	<0.001	.80
GEC*	53	56.53 (10.21)	<0.001	.64

Note. *M* = mean, *SD* = standard deviation. WAIS-IV = Wechsler Adult Intelligence Scale-IV, CVLT-II = The California Verbal Learning Test-II, CPT-3 = Conners' Continuous Performance Test-3, TMT = Trail Making Test, CWIT = Color-Word Interference Test, WCST-4 = Wisconsin Card Sorting Test-4, BRIEF-A = Behavior Rating Inventory of Executive Functioning- Adult Version, BRI = Behavior Regulation Index, MI = Metacognitive Index, GEC = Global Executive Composite.

\*One sample *t* test.

<sup>†</sup>Wilcoxon signed-rank test. Higher scores indicate better performance, except for BRIEF-A where higher scores indicate increased symptom level. The U.S. normative mean was used as comparison for BRIEF-A.

switching versus combined number letter sequencing, inhibitory control, and processing speed. Furthermore, there was no significant interaction between sex and fatigue for any of the above neurocognitive impairments (see Supplementary material, Table 1).

## Discussion

The first aim of the current study was to examine neurocognitive outcome in long-term, adult survivors of childhood ALL, treated without cranial radiation therapy. The participants had received anticancer treatment in which cranial radiation therapy was omitted, thus including a fair number of survivors treated for high-risk ALL with intensive chemotherapy only (i.e., 30% of the sample). In line with prior work in this population (Elens et al., 2017; Kanellopoulos et al., 2016; Krull et al., 2013), we report performance-based impairments within the executive functions, processing speed, and attention domains. Moreover, rates of executive functioning impairments (i.e., 26–28%) are very similar to that reported in an earlier Norwegian study (i.e., 31%) (Kanellopoulos et al., 2016). Over one decade after childhood ALL, we also report intact intellectual

abilities compared to the normative mean. This is consistent with earlier research with shorter follow-up time (Conklin et al., 2012; Krull et al., 2016), thus indicating that impairments are confined to specific neurocognitive domains. However, unlike some previous research on long-term, adult survivors (Edelmann et al., 2013; Krull et al., 2013), we did not find evidence of learning and memory impairments. Our results were more consistent with a study in younger survivors of childhood ALL (Lofstad et al., 2019), showing compensating mechanisms in relation to learning. In the present study, the first trial of CVLT (auditory attention span) was below the normative mean, but verbal learning and memory were not. This might suggest that survivors with attention impairments were able to compensate and still achieve normal learning outcomes. Still, it should be noted that the current study sample is relatively young compared to some previous studies in which broader impairments have been reported (Krull et al., 2013). Research has documented signs of accelerated aging in adult survivors of childhood ALL (Ness et al., 2018; Schuitema et al., 2021). Consequently, memory impairments may first emerge later in adulthood for some survivors (at a mean age of 31.8 according to Phillips et al., 2023).

**Table 3.** Age at diagnosis, risk group and sex as risk factors for neurocognitive outcome

	N	Standardized beta	Unstandardized beta	SE	P
<b>List A trial 1, CVLT-II</b>	51				0.31
Age at diagnosis		0.11	.22	0.30	0.47
Risk group		-0.27	-.56	0.30	0.07
Sex		-0.04	-.07	0.28	0.79
<b>Commissions, CPT-3</b>	51				0.79
Age at diagnosis		0.13	2.90	3.37	0.39
Risk group		-0.06	-1.48	3.40	0.67
Sex		0.05	.99	3.23	0.76
<b>Switching vs. combined numb. Letter seq., TMT</b>	51				0.03
Age at diagnosis		-0.03	-0.15	0.65	0.82
Risk group		-0.28	-1.36	0.66	0.04
Sex		-0.25	-1.15	0.62	0.07
<b>Color naming, CWIT</b>	51				0.31
Age at diagnosis		0.07	0.36	0.81	0.66
Risk group		-0.27	-1.54	0.82	0.07
Sex		0.07	0.37	0.78	.64
<b>GEC, BRIEF-A</b>	53				0.92
Age at diagnosis		-0.09	-1.79	3.10	0.57
Risk group		0.03	.54	3.17	0.87
Sex		-0.04	-.81	2.98	0.79
<b>MI, BRIEF-A</b>	53				0.93
Age at diagnosis		-0.003	-.07	3.25	0.98
Risk group		0.05	1.05	3.32	0.75
Sex		-0.09	-1.90	3.13	0.55

Note. For Sex: male was coded as 1, female as 0. CVLT-II = The California Verbal Learning Test 2<sup>nd</sup> edition, CPT-3 = Conners' Continuous Performance Test-3, TMT = Trail Making Test, CWIT = Color-Word Interference Test, GEC = Global Executive Composite, BRIEF-A = Behavior Rating Inventory of Executive Functioning- Adult Version, MI = Metacognitive Index.

**Table 4.** Descriptive statistics of fatigue severity and pain interference

	N	M (SD)	Min.	Max.	Impaired (%)
<b>FSS</b>	53	4.25 (1.43)	1.38	6.63	18 (34)
<b>PROMIS</b>	49	50.31 (8.86)	40.7	70.7	9 (17)

Note. M = mean, SD = standard deviation. FSS = Fatigue Severity Scale, PROMIS = patient reported outcome measure system- short form, version 1.1 pain interference, PROMIS - Pain interference reported as T-scores (M = 50, SD = 10), with impairment referring to scores 1 SD above the mean. FSS reported as raw scores, and impairment referring to FSS > 5.

Interestingly, the largest effect sizes related to neurocognitive outcome were found for self-reported executive functioning complaints (Cohens  $d = 0.59-0.99$ ). Compared with data from healthy adults from a Norwegian study (Løvstad et al., 2016), 36–47% of the sample was in the clinical range, with working memory, planning, organization, and task-monitoring being most prominent. Although healthy controls in research may not be representative of the general population, this contrasts with earlier research in long-term, adult survivors showing much lower rates (i.e., 10–16%) of executive functioning complaints (Leclerc et al., 2020; Tamnes et al., 2015). Impaired insight or long-term adaptation has previously been suggested to characterize long-term survivors in adulthood (Kanellopoulos et al., 2016; Krull et al., 2013). However, our study differs from these former studies in important ways. One earlier study (Leclerc et al., 2020) included survivors mostly treated with cranial radiation therapy. For various reasons (e.g., lower insight), this subgroup of survivors may report fewer executive functioning problems in daily life than those treated with more contemporary chemotherapy protocols. Another earlier study, conducted in Norway (Tamnes et al., 2015), did not take data from healthy Norwegian adults into account. As such, executive functioning complaints might have been underestimated. Until now, research on rehabilitation for childhood cancer survivors has focused almost exclusively on

children (Benzing et al., 2020; Conklin et al., 2015). However, the high level of executive functioning complaints reported in the present study underscores the need for executive functions rehabilitation in adult survivors as well. Since young adulthood is accompanied by increasing expectations and demands, rehabilitation directed at daily-life executive functions (Egset et al., 2021) may be especially relevant for this population.

In disagreement with our hypothesis (Fellah et al., 2019; Krull et al., 2013), participants treated with high-risk ALL protocols did not demonstrate poorer neurocognitive outcome compared to those with a non-high-risk treatment. Additionally, we did not find support for the hypothesis stating female sex as a risk factor for poor neurocognitive outcome. Previous research has identified female sex and treatment burden as risk factors for neurocognitive sequelae in adulthood (Krull et al., 2013; van der Plas, Qiu, et al., 2021). Still, these studies were conducted with much larger samples than ours (Krull et al., 2013; van der Plas, Qiu, et al., 2021). Thus, any potential effects may not have been large enough to be detected in the current sample size. In addition, associations have typically been established with specific chemotherapeutic agents (e.g., methotrexate, Phillips et al., 2023), which were not investigated in this study. Furthermore, since the mean age at diagnosis in this study was 10 years, we compared neurocognitive outcome above and below this age. Previous studies in younger survivors have shown that being diagnosed before age five is a neurocognitive risk factor (Conklin et al., 2012; Jacola et al., 2016; Sherief et al., 2018). Still, none of the comparisons between groups showed significant differences in neurocognitive outcome in the current study. However, relatively few had been treated before the age of five, which may have impacted the results. Importantly, other factors may become more influential as survivors progress into young adulthood. This is why we also examined the impact of fatigue severity and pain interference on neurocognitive outcome.

Fatigue severity was the present study's most significant predictor of neurocognitive outcome. In agreement with our

**Table 5.** Fatigue severity and pain interference as predictors of neurocognitive outcome

	<i>N</i>	Standardized beta	Unstandardized beta	SE	<i>P</i>
<b>List A trial 1, CVLT-II</b>	47				
FSS		0.1897415	-0.13	0.1108256	0.2748
PROMIS		-0.0815902	-0.01	0.0176906	0.257
<b>Commissions, CPT-3</b>					0.624
FSS		-0.34	-2.61	1.24	0.1188
PROMIS		0.14	0.17	0.20	0.041
<b>Switching vs. combined, TMT</b>	47				0.397
FSS		0.2480193	0.37	0.25	0.1581
PROMIS		0.0642315	0.02	0.04	0.136
<b>Color naming, CWIT</b>	47				0.696
FSS		-0.0599648	-0.12	0.321577	0.4671
PROMIS		-0.1487923	-0.05	0.0513319	0.722
<b>GEC, BRIEF-A</b>	49				0.378
FSS		0.5467883	3.87	0.99	<0.001***
PROMIS		-0.0034353	-0.00	0.16	<0.001***
<b>MI, BRIEF-A</b>	49				0.98
FSS		0.448	3.33	1.091	0.003**
PROMIS		0.051	0.06	0.176	0.004**
					0.732

Note. CVLT-II = The California Verbal Learning Test 2<sup>nd</sup> edition, FSS = Fatigue Severity Scale, PROMIS = patient reported outcome measure system- short form, version 1.1 pain interference, CPT-3 = Conners' Continuous Performance Test-3, TMT = Trail Making Test, CWIT = Color-Word Interference Test, GEC = Global Executive Composite, BRIEF-A = Behavior Rating Inventory of Executive Functioning- Adult Version, MI = Metacognitive Index.

expectation, more severe fatigue was associated with poorer neurocognitive outcomes (i.e., executive functioning complaints). Survivors with severe fatigue were more likely to report difficulties with the regulation of thoughts and goal-directed behavior in adult daily-life. This is in accordance with earlier studies showing a relationship between fatigue and neurocognitive impairments (e.g., having received special education services) (Meeske et al., 2005; Rueegg et al., 2013). The association between fatigue and executive functions may have implications for rehabilitation. As both fatigue and executive functions are potentially modifiable, future research should explore whether specific interventions (e.g., cognitive, and physical rehabilitation) could have a favorable impact on both outcomes in this population.

A strength of our study was the examination of fatigue in relation to neurocognitive performance in addition to self-reports. Still, no associations with performance-based measures were found. The adaptation of the testing schedule to accommodate participants with severe fatigue could have masked some of the effects of fatigue on test performance. It should also be noted that the current study only measured fatigue at one timepoint. Although severe fatigue in long-term survivorship can be an indication of chronic fatigue, the association between executive functions and fatigue over time (i.e., chronic fatigue) was not specifically examined. Furthermore, neurocognition in females was no more affected by fatigue than that of males. It is possible that sex differences previously detected by Cheung et al. (2017) are more salient in adolescence, in which females can be particularly vulnerable (Pfeifer & Allen, 2021). Still, our results are consistent with several other studies in the childhood cancer literature, that have reported similar levels of fatigue among males and females (Frederick et al., 2016; Irestorm et al., 2023; Zeller et al., 2014).

Somewhat surprisingly, we found no associations between neurocognitive sequelae and pain interference. However, existing research suggests that interference of pain is more frequent in survivors of soft-tissue sarcomas, non-Hodgkins lymphoma, Ewing sarcoma and/or osteosarcoma, and in those above the age of 30 years (Tonning Olsson et al., 2021). Thus, the impact of pain interference on neurocognition may be less evident in long-term survivors of childhood ALL, in young adulthood. Recent research (Partanen et al., 2022), in younger survivors of childhood ALL, has, however, demonstrated associations

between neuropathic pain and neurocognition. These specific associations warrant further study in long-term, adult survivors.

### Strengths and limitations

This study is limited by a cross-sectional design. Pretreatment neurocognitive testing was not performed, which prevents any comparison to baseline performance. Thus, it is possible that other factors unrelated to disease and treatment have influenced the neurocognitive outcome of the studied sample. Another limitation of the current study is that it did not include a control group, which limits the conclusions that can be drawn regarding the neurocognitive outcome measures. This pertains especially to outcomes where Norwegian normative data was not available. Still, all neurocognitive measures used are standardized, and participants were compared with age-adjusted normative data, frequently used in Norwegian clinical practice.

The data reported in this manuscript was collected during the Covid-19 pandemic. Although recruitment continued until after the Norwegian society officially was back to normal everyday life, the data collection process was likely affected by the pandemic. The response rate was not optimal (overall 40% response rate). Although age at diagnosis was not available for all eligible non-participants, results suggested that participants were older at diagnosis (median = 12.00) compared to non-participants. Scandinavian children with leukemia are most frequently diagnosed at ages 1–5 years (National Quality Registry for Childhood Cancer, 2022), with a median of five years for those diagnosed with ALL before age 16 (Gustafsson et al., 2013). Hence, a possible selection bias should be kept in mind when interpreting the results. A younger age at diagnosis has been associated with more neurocognitive sequelae (Sherief et al., 2018). As such, the higher age at diagnosis in the current sample might influence the results in the direction of false negative findings. At the same time, the present study may also have attracted more individuals with neurocognitive complaints due to the inherent focus on neurocognitive sequelae (i.e., due to the associated clinical trial of cognitive rehabilitation). Furthermore, while the current sample was small compared to previous reports in long-term, adult survivors (Kanellopoulos et al., 2016; Krull et al., 2013), our study is unique in presenting long-term adult survivors treated with Nordic protocols in

which cranial radiation therapy was largely or totally omitted (Schmiegelow et al., 2010; Toft et al., 2018). The inclusion of participants from two of Norway's largest pediatric hospitals (St Olavs Hospital and Oslo University Hospital), should also be considered a strength of the study, covering >60 % of the Norwegian childhood cancer population.

## Conclusion

Long-term adult survivors of childhood ALL, treated without cranial radiation therapy demonstrate intact intellectual capacity and discrete neurocognitive impairments. However, continued neurocognitive follow-up of this group of survivors later in adulthood will be an important task for future research. Executive functions complaints in the metacognitive domain (i.e., working memory, planning, organization, task-monitoring) were frequently reported, which might indicate a need for rehabilitation programs targeting real-life functioning. The only significant predictor of neurocognitive impairment was fatigue severity, irrespective of survivor sex. The association between fatigue and executive functioning complaints may have implications for rehabilitation.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S1355617724000080>.

**Acknowledgments.** This study was funded by the Norwegian Cancer Society, with grant number 201842. Data were stored and managed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo. The authors would like to thank Elna Hamilton Larsen and Katrine Aass Underhaug for assisting with medical journal extraction at Oslo University Hospital. The authors would also like to thank Magnhild Eitrem Røkke and Lisbet Moen for contributing to data collection in Trondheim and Synne Stadheim Øiestad, Henriette Hofsoy and Mari Arnesen for data collection in Oslo.

**Competing interests.** The authors have no conflicts of interest to declare.

## References

- Benzing, V., Spitzhüttl, J., Siegwart, V., Schmid, J., Grotzer, M., Heinks, T., Roebers, C., Steinlin, M., Leibundgut, K., Schmidt, M., & Everts, R. (2020). Effects of cognitive training and exergaming in pediatric cancer survivors—a randomized clinical trial. *Medicine and Science in Sports and Exercise*, 52(11), 2293–2302.
- Bersvendsen, H., Kolstad, A., Blystad, A. K., Aurlien, E., Fosså, A., Kvaløy, S. O., Holte, H., & Lauritzen, G. F. (2014). Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma. *Acta Oncologica*, 53(5), 680–687.
- Biondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., Li, C.-K., Vora, A., Arico, M., Röttgers, S., Saha, V., & Valsecchi, M. G. (2012). Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. *The Lancet Oncology*, 13(9), 936–945.
- Bowers, D. C., Griffith, T., Gargan, L., Cochran, C. J., Kleiber, B., Foxwell, A., Farrow-Gillespie, A., Orlino, A., & Germann, J. N. (2012). Back pain among long-term survivors of childhood leukemia. *Journal of Pediatric Hematology/Oncology*, 34(8), 624–629.
- Cheung, Y. T., Brinkman, T. M., Mulrooney, D. A., Mzayek, Y., Liu, W., Banerjee, P., Panoskaltis-Mortari, A., Srivastava, D., Pui, C-Hon, Robison, L. L., Hudson, M. M., & Krull, K. R. (2017). Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia. *Cancer*, 123(17), 3410–3419.
- Cheung, Y. T., & Krull, K. R. (2015). Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review. *Neuroscience & Biobehavioral Reviews*, 53, 108–120.
- Chiou, S. S., Lin, P. C., Liao, Y. M., & Yang, P. (2019). A cross-sectional follow-up study of physical morbidities, neurocognitive function, and attention problems in post-treatment childhood acute lymphoblastic leukemia survivors. *The Kaohsiung Journal of Medical Sciences*, 35(6), 373–378.
- Clanton, N. R., Klosky, J. L., Li, C., Jain, N., Srivastava, D. K., Mulrooney, D., Zeltzer, L., Stovall, M., Robison, L. L., & Krull, K. R. (2011). Fatigue, vitality, sleep, and neurocognitive functioning in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. *Cancer*, 117(11), 2559–2568.
- Conklin, H. M., Krull, K. R., Reddick, W., Pei, D., Cheng, C., & Pui, C. (2012). Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia. *Journal of the National Cancer Institute*, 104(18), 1386–1395.
- Conklin, H. M., Ogg, R. J., Ashford, J. M., Scoggins, M. A., Zou, P., Clark, K. N., Martin-Elbahesh, K., Hardy, K. K., Merchant, T. E., Jeha, S., Huang, L., & Zhang, H. (2015). Computerized cognitive training for amelioration of cognitive late effects among childhood cancer survivors: A randomized controlled trial. *Journal of Clinical Oncology*, 33(33), 3894–3902.
- Conners, C. K. (2014). *Conners' continuous performance test (CPT3)*. Multi-Health Systems.
- Delis, D. C., Kaplan, E., & Kramer, J. H. (2001). *Delis-Kaplan executive function system*. NCS Pearson, Inc.
- Edelmann, M. N., Ogg, R. J., Scoggins, M. A., Brinkman, T. M., Sabin, N. D., Pui, C.-H., Srivastava, D. K., Robison, L. L., Hudson, M. M., & Krull, K. R. (2013). Dexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia: A report from the SJLIFE cohort. *Pediatric Blood & Cancer*, 60(11), 1778–1784.
- Egset, K. S., Weider, S., Stubberud, J., Hjemdal, O., Ruud, E., Hjort, M. A., Eilertsen, M.-E. B., Sund, A. M., Røkke, M. E., & Reinjfell, T. (2021). Cognitive rehabilitation for neurocognitive late effects in adult survivors of childhood acute lymphoblastic leukemia: A feasibility and case-series study. *Frontiers in Psychology*, 12, 1–12.
- Elens, I., Deprez, S., Danckaerts, M., Bijttebier, P., Labarque, V., Uyttebroeck, A., Van Gool, S., D'Hooge, R., & Lemiere, J. (2017). Neurocognitive sequelae in adult childhood leukemia survivors related to levels of phosphorylated tau. *JNCI: Journal of the National Cancer Institute*, 109(7), 1–4.
- Fellah, S., Cheung, Y. T., Scoggins, M. A., Zou, P., Sabin, N. D., Pui, C.-H., Robison, L. L., Hudson, M. M., Ogg, R. J., & Krull, K. R. (2019). Brain activity associated with attention deficits following chemotherapy for childhood acute lymphoblastic leukemia. *JNCI: Journal of the National Cancer Institute*, 111(2), 201–209.
- Frederick, N. N., Kenney, L., Vrooman, L., & Recklitis, C. J. (2016). Fatigue in adolescent and adult survivors of non-CNS childhood cancer: A report from project REACH. *Supportive Care in Cancer*, 24(9), 3951–3959.
- Friedman, N. P., & Miyake, A. (2017). Unity and diversity of executive functions: Individual differences as a window on cognitive structure. *Cortex*, 86, 186–204.
- Gencay-Can, A., & Can, S. S. (2012). Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. *Rheumatology International*, 32(1), 27–31.
- Gioia, G. A. (2000). *Behavior rating inventory of executive function: Professional manual*. Psychological Assessment Resources, Incorporated.
- Gustafsson, G., Kogner, P., & Heyman, M. *Childhood Cancer Incidence and Survival in Sweden 1984-2010* (2013). <https://sbc.se/index.php/rapporter/>.
- Hamre, H., Zeller, B., Kanellopoulos, A., Kiserud, C. E., Aakhus, S., Lund, M. B., Loge, J. H., Fosså, S. D., & Ruud, E. (2013). High prevalence of chronic fatigue in adult long-term survivors of acute lymphoblastic leukemia and lymphoma during childhood and adolescence. *Journal of Adolescent and Young Adult Oncology*, 2(1), 2–9.
- Hardy, S. J., Krull, K. R., Wefel, J. S., & Janelins, M. (2018). Cognitive changes in cancer survivors. *American Society of Clinical Oncology Educational Book*, 38(38), 795–806.
- Heaton, R. K., & Staff, P. (1993). *Wisconsin card sorting test: computer version 2* (vol. 4, pp. 1–4). Psychological Assessment Resources.
- Hudson, M. M., Neglia, J. P., Woods, W. G., Sandlund, J. T., Pui, C-Hon, Kun, L. E., Robison, L. L., & Green, D. M. (2012). Lessons from the past: Opportunities to improve childhood cancer survivor care through



- outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. *Pediatric Blood & Cancer*, 58(3), 334–343.
- Irestorm, E., Steur, L. M. H., Kaspers, G. J. L., Van Eijkelenburg, N. K. A., Van der Sluis, I. M., Dors, N., Van den Bos, C., Tissing, W. J. E., Grootenhuys, M. A., & Van Litsenburg, R. R. L. (2023). Fatigue trajectories during pediatric ALL therapy are associated with fatigue after treatment: A national longitudinal cohort study. *Supportive Care in Cancer*, 31(1), 1–9.
- Jacola, L. M., Krull, K. R., Pui, C.-H., Pei, D., Cheng, C., Reddick, W. E., & Conklin, H. M. (2016). Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol. *Journal of Clinical Oncology*, 34(11), 1239–1247.
- Jeha, S., Pei, D., Choi, J., Cheng, C., Sandlund, J. T., Coustan-Smith, E., Campana, D., Inaba, H., Rubnitz, J. E., Ribeiro, R. C., Gruber, T. A., Raimondi, S. C., Khan, R. B., Yang, J. J., Mullighan, C. G., Downing, J. R., Evans, W. E., Relling, M. V., & Pui, C.-H. (2019). Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. *Journal of Clinical Oncology*, 37(35), 3377–3391.
- Kandula, T., Park, S. B., Cohn, R. J., Krishnan, A. V., & Farrar, M. A. (2016). Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. *Cancer Treatment Reviews*, 50, 118–128.
- Kanellopoulos, A., Andersson, S., Zeller, B., Tamnes, C. K., Fjell, A. M., Walhovd, K. B., Westlye, L. T., Fosså, S. D., & Ruud, E. (2016). Neurocognitive outcome in very long-term survivors of childhood acute lymphoblastic leukemia after treatment with chemotherapy only. *Pediatric Blood & Cancer*, 63(1), 133–138.
- Kanellopoulos, A., Hamre, H. M., Dahl, A. A., Fosså, S. D., & Ruud, E. (2013). Factors associated with poor quality of life in survivors of childhood acute lymphoblastic leukemia and lymphoma. *Pediatric Blood & Cancer*, 60(5), 849–855.
- Khan, R. B., Hudson, M. M., Ledet, D. S., Morris, E. B., Pui, C.-H., Howard, S. C., Krull, K. R., Hinds, P. S., Crom, D., Browne, E., Zhu, L., Rai, S., Srivastava, D., & Ness, K. K. (2014). Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: A prospective cross-sectional study. *Journal of Cancer Survivorship*, 8(4), 688–696.
- Kleinman, L., Zodet, M. W., Hakim, Z., Aledort, J., Barker, C., Chan, K., Krupp, L., & Revicki, D. (2000). Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. *Quality of Life Research*, 9(5), 499–508.
- Krull, K. R., Brinkman, T. M., Li, C., Armstrong, G. T., Ness, K. K., Srivastava, D. K., Gurney, J. G., Kimberg, C., Krasin, M. J., Pui, C.-H., Robison, L. L., & Hudson, M. M. (2013). Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: A report from the St Jude lifetime cohort study. *Journal of Clinical Oncology*, 31(35), 4407–4415.
- Krull, K. R., Cheung, Y. T., Liu, W., Fella, S., Reddick, W. E., Brinkman, T. M., Kimberg, C., Ogg, R., Srivastava, D., Pui, C.-H., Robison, L. L., & Hudson, M. M. (2016). Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. *Journal of Clinical Oncology*, 34(22), 2644–2653.
- Krull, K. R., Hardy, K. K., Kahalley, L. S., Schuitema, I., & Kesler, S. R. (2018). Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. *Journal of Clinical Oncology*, 36(21), 2181–2189.
- Krupp, L. B., Alvarez, L. A., LaRocca, N. G., & Scheinberg, L. C. (1988). Fatigue in multiple sclerosis. *Archives of Neurology*, 45(4), 435–437.
- Krupp, L. B., LaRocca, N. G., Muir-Nash, J., & Steinberg, A. D. (1989). The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. *Archives of Neurology*, 46(10), 1121–1123.
- Leclerc, A.-A., Lippé, S., Bertout, L., Chapados, P., Boulet-Craig, A., Drouin, S., Krajcinovic, M., Laverdière, C., Michon, B., Robaey, P., Rondeau, É., Sinnott, D., & Sultan, S. (2020). Inconsistencies between measures of cognitive dysfunction in childhood acute lymphoblastic leukemia survivors: Description and understanding. *Psycho-Oncology*, 29(7), 1201–1208.
- Lerdal, A. (2021). Fatigue severity scale. In *Encyclopedia of quality of life and well-being research* (pp. 1–5). Springer.
- Lerdal, A., Wahl, A. K., Rustoen, T., Hanestad, B. R., & Moum, T. (2005). Fatigue in the general population: A translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. *Scandinavian Journal of Public Health*, 33(2), 123–130.
- Lezak, M. D., Howieson, D. B., Bigler, E. D., & Tranel, D. (2012). *Neuropsychological assessment*. Oxford University Press.
- Lofstad, G. E., Reinfjell, T., Weider, S., Diseth, T. H., & Hestad, K. (2019). Neurocognitive outcome and compensating possibilities in children and adolescents treated for acute lymphoblastic leukemia with chemotherapy only. *Frontiers in Psychology*, 10, 1027.
- Løvstad, M., Sigurdardottir, S., Andersson, S., Grane, V., Moberget, T., Stubberud, J., & Solbakk, A. (2016). Behavior rating inventory of executive function adult version in patients with neurological and neuropsychiatric conditions: Symptom levels and relationship to emotional distress. *Journal of the International Neuropsychological Society*, 22(6), 682–694.
- Meeske, K. A., Siegel, S. E., Globe, D. R., Mack, W. J., & Bernstein, L. (2005). Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. *Journal of Clinical Oncology*, 23(24), 5501–5510.
- Miyake, A., & Friedman, N. P. (2012). The nature and organization of individual differences in executive functions: Four general conclusions. *Current Directions in Psychological Science*, 21(1), 8–14.
- Moriarty, O., McGuire, B. E., & Finn, D. P. (2011). The effect of pain on cognitive function: A review of clinical and preclinical research. *Progress in Neurobiology*, 93(3), 385–404.
- National Quality Registry for Childhood Cancer. Annual Report 2022 (2022). <https://www.kreftregisteret.no/Generelt/Rapporter/Arssrapport-fra-kvalitetsregistre/Arssrapport-for-barnekreft/arsrapport-for-barnekreft-2022/>.
- Ness, K. K., Hudson, M. M., Jones, K. E., Leisenring, W., Yasui, Y., Chen, Y., Stovall, M., Gibson, T. M., Green, D. M., Neglia, J. P., Henderson, T. O., Casillas, J., Ford, J. S., Effinger, K. E., Krull, K. R., Armstrong, G. T., Robison, L. L., Oeffinger, K. C., & Nathan, P. C. (2017). Effect of temporal changes in therapeutic exposure on self-reported health status in childhood cancer survivors. *Annals of Internal Medicine*, 166(2), 89–98.
- Ness, K. K., Kirkland, J. L., Gramates, M. M., Wang, Z., Kundu, M., McCastlain, K., Li-Harms, X., Zhang, J., Tchkonja, T., Pluijms, S. M. F., & Armstrong, G. T. (2018). Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer. *Journal of Clinical Oncology*, 36(21), 2206–2215.
- Partanen, M., Alberts, N. M., Conklin, H. M., Krull, K. R., Pui, C.-H., Anghelescu, D. A., & Jacola, L. M. (2022). Neuropathic pain and neurocognitive functioning in children treated for acute lymphoblastic leukemia. *Pain*, 163(6), 1070–1077.
- Pfeifer, J. H., & Allen, N. B. (2021). Puberty initiates cascading relationships between neurodevelopmental, social, and internalizing processes across adolescence. *Biological Psychiatry*, 89(2), 99–108.
- Phillips, N. S., Stratton, K. L., Williams, A. L. M., Ahles, T., Ness, K. K., Cohen, H. J., Edelstein, K., Yasui, Y., Oeffinger, K., Chow, E. J., Howell, R. M., Robison, L. L., Armstrong, G. T., Leisenring, W. M., & Krull, K. R. (2023). Late-onset cognitive impairment and modifiable risk factors in adult childhood cancer survivors. *JAMA Network Open*, 6(5), e2316077–e2316077.
- Pui, C.-H., & Evans, W. E. (2013). A 50-year journey to cure childhood acute lymphoblastic leukemia. In *Paper presented at the Seminars in Hematology* Rimehaug, S. A., Kaat, A. J., Nordvik, J. E., Klokkerud, M., & Robinson, H. S. (2022). Psychometric properties of the PROMIS-57 questionnaire, Norwegian version. *Quality of Life Research*, 31(1), 269–280.
- Roth, R. M., Gioia, G. A., & Isquith, P. K. (2005). *BRIEF-A: Behavior rating inventory of executive function—adult version*. Psychological Assessment Resources.
- Rueegg, C. S., Gianinazzi, M. E., Rischewski, J., Beck Popovic, M., von der Weid, N. X., Michel, G., & Kuehni, C. E. (2013). Health-related quality of life in survivors of childhood cancer: The role of chronic health problems. *Journal of Cancer Survivorship*, 7(4), 511–522.
- Schanke, A.-K., Stanghelle, J. K., Andersson, S., Opheim, A., Strom, V., & Solbakk, A.-K. (2002). Mild versus severe fatigue in polio survivors: Special characteristics. *Journal of Rehabilitation Medicine*, 34(3), 134–140.
- Schmiegelow, K., Forestier, E., Hellebostad, M., Heyman, M., Kristinsson, J., Söderhäll, S., & Taskinen, M. (2010). Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. *Leukemia*, 24(2), 345–354.

- Schuitema, I., Alexander, T., Hudson, M. M., Krull, K. R., & Edelstein, K. (2021). Aging in adult survivors of childhood cancer: Implications for future care. *Journal of Clinical Oncology*, 39(16), 1741–1751.
- Sherief, L. M., Sanad, R., ElHaddad, A., Shebl, A., Abdelkhalek, E. R., Elsafy, E. R., & Attia, E. I. (2018). A cross-sectional study of two chemotherapy protocols on long term neurocognitive functions in Egyptian children surviving acute lymphoblastic leukemia. *Current Pediatric Reviews*, 14(4), 253–260.
- Stone, A. L., Karlson, C. W., Heathcote, L. C., Rosenberg, A. R., & Palermo, T. M. (2018). Topical review: Pain in survivors of pediatric cancer: Applying a prevention framework. *Journal of Pediatric Psychology*, 43(3), 237–242.
- Tamnes, C. K., Zeller, B., Amlien, I. K., Kanellopoulos, A., Andersson, S., Due-Tønnessen, P., Ruud, E., Walhovd, K. B., & Fjell, A. M. (2015). Cortical surface area and thickness in adult survivors of pediatric acute lymphoblastic leukemia. *Pediatric Blood & Cancer*, 62(6), 1027–1034.
- Toft, N., Birgens, H., Abrahamsson, J., Griškevičius, L., Hallböök, H., Heyman, M., Klausen, T. W., Jónsson, ÓG., Palk, K., Pruunsild, K., Quist-Paulsen, P., Vaitkeviciene, G., Vettenranta, K., Åsberg, A., Frandsen, T. L., Marquart, H. V., Madsen, H. O., Norén-Nyström, U., & Schmiegelow, K. (2018). Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. *Leukemia*, 32(3), 606–615.
- Tonning Olsson, I., Alberts, N. M., Li, C., Ehrhardt, M. J., Mulrooney, D. A., Liu, W., Pappo, A. S., Bishop, M. W., Anghelescu, D. L., Srivastava, D., Robison, L. L., Hudson, M. M., Ness, K. K., Krull, K. R., & Brinkman, T. M. (2021). Pain and functional outcomes in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study. *Cancer*, 127(10), 1679–1689.
- van der Plas, E., Modi, A. J., Li, C. K., Krull, K. R., & Cheung, Y. T. (2021). Cognitive impairment in survivors of pediatric acute lymphoblastic leukemia treated with chemotherapy only. *Journal of Clinical Oncology*, 39(16), 1705–1717.
- van der Plas, E., Qiu, W., Nieman, B. J., Yasui, Y., Liu, Q., Dixon, S. B., Jacola, L. M., Kadan-Lottick, N. S., Weldon, C. B., Weil, B. R., Jacola, L. M., Gibson, T. M., Leisenring, W., Oeffinger, K., Hudson, M. M., Robison, L. L., Armstrong, G. T., & Krull, K. R. (2021). Sex-specific associations between chemotherapy, chronic conditions, and neurocognitive impairment in acute lymphoblastic leukemia survivors: A report from the childhood cancer survivor study. *JNCI: Journal of the National Cancer Institute*, 113(5), 588–596.
- van Deuren, S., Boonstra, A., van Dulmen-den Broeder, E., Blijlevens, N., Knoop, H., & Loonen, J. (2020). Severe fatigue after treatment for childhood cancer. *Cochrane Database of Systematic Reviews*, 3(3), CD012681.
- van Deuren, S., Penson, A., van Dulmen-den Broeder, E., Grootenhuis, M. A., van der Heiden-van der Loo, M., Bronkhorst, E., Blijlevens, N. M. A., Streefkerk, N., Teepe, J. C., Tissing, W. J., van der Pal, H. J. H., van den Heuvel-Eibrink, M. M., Versluys, B. A. B., Bresters, D., van Leeuwen, F. E., Ronckers, C. M., Kremer, L. C. M., Knoop, H., & Loonen, J. J. (2022). Prevalence and risk factors of cancer-related fatigue in childhood cancer survivors: A DCCSS LATER study. *Cancer*, 128(5), 1110–1121.
- von Stackelberg, A., Bourquin, J.-P., Zimmermann, M., Revesz, T., Attarbaschi, A., Ferster, A., & Elhasid, R. (2022). ALL-REZ BFM 2002 is associated with improved outcome as compared to ALL-r3 strategy in children with standard risk isolated CNS relapse of acute lymphoblastic leukemia, while maintaining comparable efficacy in patients with bone marrow relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010. *Blood*, 140(Supplement 1), 3247–3249.
- von Stackelberg, A., Qi, C., Saha, V., Locatelli, F., Moschandreas, J., & Love, S. (2017). *IntReALL S.R. 2010: An international randomised phase III study for the treatment of standard risk childhood relapsed acute lymphoblastic leukaemia*. University of Oxford.
- Weschler, D. (2008). *Weschler Adult Intelligence Scale*. NCS Pearson.
- Zeller, B., Loge, J. H., Kanellopoulos, A., Hamre, H., Wyller, V. B., & Ruud, E. (2014). Chronic fatigue in long-term survivors of childhood lymphomas and leukemia: Persistence and associated clinical factors. *Journal of Pediatric Hematology/Oncology*, 36(6), 438–444.
- Zhou, C., Zhuang, Y., Lin, X., Michelson, A. D., & Zhang, A. (2020). Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: A meta-analysis. *British Journal of Haematology*, 188(6), 945–961.